BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 12926112)

  • 21. Granisetron: is there a dose-response effect on nausea and vomiting?
    Minami M
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):89-98. PubMed ID: 12783208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting.
    Loewen PS; Marra CA; Zed PJ
    Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.
    Yamakuni H; Sawai H; Maeda Y; Imazumi K; Sakuma H; Matsuo M; Mutoh S; Seki J
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
    Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
    Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropharmacology of emesis in relation to clinical response.
    Costall B; Naylor RJ
    Br J Cancer Suppl; 1992 Dec; 19():S2-7; discussion S7-8. PubMed ID: 1467196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiemetics revisited.
    Roila F; Del Favero A
    Curr Opin Oncol; 1997 Jul; 9(4):321-6. PubMed ID: 9251881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
    Martin C; Roman V; Agay D; Fatôme M
    Radiat Res; 1998 Jun; 149(6):631-6. PubMed ID: 9611102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting.
    Spitzer TR; Grunberg SM; Dicato MA
    Support Care Cancer; 1998 May; 6(3):233-6. PubMed ID: 9629875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of antiemetic drugs.
    Jordan K; Schmoll HJ; Aapro MS
    Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
    Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
    Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
    Lee CY; Ratnapalan S; Thompson M; Nathan PC; Closs J; French A; Punnett A; Garcia-Bournissen F; Ito S; Koren G
    Can J Clin Pharmacol; 2010; 17(1):e1-4. PubMed ID: 20051608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5HT3-antagonist receptors: their role in drug-induced emesis.
    Dieras V; Extra JM; Le Bonniec M; Madelaine I; Espie M; Marty M
    Nouv Rev Fr Hematol (1978); 1990; 32(6):449-52. PubMed ID: 1983228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compatibility and stability of 5-HT3 receptor antagonists: a pharmacology review.
    Longfield V
    Oncol Nurs Forum; 2002; 29(10):1469-82. PubMed ID: 12432417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granisetron: relating pharmacology to clinical efficacy.
    Blower PR
    Support Care Cancer; 2003 Feb; 11(2):93-100. PubMed ID: 12560937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
    Vrabel M
    Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.